Handelsavisen
prelaunch
Companies Healthcare EBM.V
EB
EBM.V TSX Venture Pharmaceuticals

Ebm.V

$0,95
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-42,5 %
ROE
20,4 %
Net margin
-42,5 %
Debt / equity
-0,05
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

EBM.V operates in the pharmaceuticals industry, focusing on the development and commercialization of medical products and services.

Business. EBM.V operates in the pharmaceuticals industry, focusing on the development and commercialization of medical products and services.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
20,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning EBM.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to EBM.V. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    EBM.V operates in the pharmaceuticals industry, focusing on the development and commercialization of medical products and services.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    EBM.V's capital structure is highly leveraged, with total liabilities of CAD 1.85 billion and total equity of CAD -1.63 billion, resulting in a negative debt-to-equity ratio of -0.05. The company's liquidity position is weak, as indicated by a current ratio of 0.02, suggesting significant short-term financial stress. Free cash flow is negative at CAD -287.81 million, further highlighting the company's inability to generate sufficient cash from operations to fund its activities.

    Profitability metrics show a stark contrast to industry norms. Gross profit of CAD 550.99 million is positive, but operating income is a loss of CAD 332.77 million, and net income is also a loss of CAD 332.77 million. Return on equity is 20.42%, which is unusually high given the negative equity position, and return on assets is -1.52%, indicating poor asset utilization. These figures suggest the company is not generating returns that meet industry expectations.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the company's ability to offset losses in one area with gains in another.

    Growth trajectory is negative, with no disclosed revenue growth in the current fiscal year. The company is expected to continue facing financial challenges in the next fiscal year, with no clear path to profitability or improved liquidity. Historical revenue trends show a decline, and there are no indications of a turnaround in the near term.

    Risk factors include high liquidity risk due to negative working capital and a negative net cash position after subtracting total debt. The company's dilution potential is low, but the negative equity position and high leverage increase the risk of further dilution if the company needs to raise additional capital. No recent events or filings have been disclosed that would indicate a change in the company's financial strategy or operations.

    Key takeaways
    • EBM.V has a highly leveraged capital structure with a negative equity position.
    • The company is not generating positive operating or net income, indicating poor profitability.
    • Liquidity is critically low, with a current ratio of 0.02 and negative free cash flow.
    • Revenue is concentrated in a single segment, increasing exposure to market-specific risks.
    • The company is expected to continue facing financial challenges in the next fiscal year.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,95
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$1.6M
    Net cash
    -$78.0k
    Current ratio
    0.0
    Debt / equity
    -0.1
    ROA
    -1.5%
    ROE
    20.4%
    Cash conversion
    -6.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-42,5 %Bottom quartile
    Net Margin-42,5 %Bottom quartile
    ROE20,4 %Best in class
    D/E-0,05Above P75
    Cash Conv-0,06Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • EBM.V Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    EBM.VCanonical
    TSX Venture · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage